MDXHealth SA (NASDAQ:MXDHF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday. The firm presently has a $6.25 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 5.93% from the stock’s current price.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

Shares of MDXHealth SA (NASDAQ:MXDHF) opened at 5.90 on Tuesday. The firm’s 50-day moving average is $5.78 and its 200-day moving average is $5.68. MDXHealth SA has a 12-month low of $4.77 and a 12-month high of $6.15. The firm’s market cap is $294.70 million.

WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

Get a free copy of the Zacks research report on MDXHealth SA (MXDHF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for MDXHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth SA and related companies with Analyst Ratings Network's FREE daily email newsletter.